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restraints and objections about the viability of the fund are still a matter of debate,
focused particular on the development of a flexible mechanism for primary health
care that will ensure equitable access and benefits for members and improve the
quality of services.
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OBJECTIVES: Price capping of generics against the originator (also known as price
linkage) has been in use for some time despite studies questioning its efficacy as a
cost-containment mechanism. In particular, a 2007 study from Norway – where
internal reference and generic price linkage to the originator co-existed for some
time - found that both originator and generic prices fell significantly, but the price
decline impact was sharper for originator drugs in the reference pricing group than
in the price caps group. This study seeks to evaluate if price capping remains a
policy of choice in the current austerity climate. METHODS: Research focused on a
review of current pricing and reimbursement (P&R) regulations for generics in
European Union countries and major markets outside the EU to identify which
countries have adopted or are in the process of adopting new price caps or have
amended existing price caps for generics versus the originator from the start of
2010 to date. The review includes both original laws related to price capping and
interpretation of the place of price linkage in each country’s pharmaceutical P&R
system from secondary sources and from IHS Global Insight’s proprietary Same
Day Analysis archive. RESULTS: France, Portugal, Hungary, the Czech Republic,
Romania, Slovakia, Greece, Japan and Canada are among the countries which have
recently amended their use of price linkage in an attempt to contain pharmaceu-
tical spending.CONCLUSIONS:While price caps remain popular, it is rare for coun-
tries to use them in isolation. Internal reference pricing is typically also in use.
Among countries which have recently made changes to their price linkage system,
Romania, Hungary and Poland have also undertaken changes to their internal
reference pricing system, as governments attempt to tackle the cost-containment
paradigm from all sides.
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OBJECTIVES: To analyze the influence of regulatory changes for medicines pricing
and reimbursement on medicines prices. METHODS: Regulatory analysis was per-
formed towards the Drug Law, Regulation on positive drug list (PDL), and on med-
icines reimbursement rules. All medicines affected by the changes were system-
ized by the way of dispensing and financing. Comparative analysis of the changes
in medicines prices before and after 30 of March 2011 was developed as well a year
later for absolute and relative change of the prices. RESULTS: The pricing and
reimbursement processes are controlled by the Pricing and reimbursement com-
mittee within MoH. Medicines are separated in two groups according to their price
control – with registration of maximal retails prices for OTC and out of the reim-
bursement list (30 days procedure); and regulation of prices for publicly financed
medicines (60 days procedure) by inclusion into the PDL. In the beginning of 2011
the Ministry council initiated regulatory changes. 150 INN of medicines that were
financed via the centralized procurement procedures organized by the MoH were
separated in 2 groups. 82 INN for outpatient care were transferred to national
health insurance fund (NHIF) and 68 for inpatient care to hospitals. For the 82 INN
were changed not only the procurement and financing institution but also the way
of prices establishment through regulated as reference prices with regressive mar-
gins. Only 5 medicines decrease their prices after the transformation, but a year
later all medicines decreased their prices. For the medicines transferred to hospi-
tals the biggest hospitals managed to contract lower prices than before but small
ones were unable to do so. In general total cost of the supplied medicines weighed
by quantity procured was lower than before the changes. CONCLUSIONS: Regula-
tory changes led to positive economic impact but still the long term consequences
remain unclear for all medicines.
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OBJECTIVES: Patient access schemes (PAS) are commonly used in the UK as a way
to reduce a drug’s Incremental Cost Effectiveness (ICER) per Quality Adjusted Life
Year (QALY) ratio and gain NICE acceptance without reducing the list price. With
the advent of value based pricing (VBP) in 2014, the role of PAS is expected to
change. This study examines if PAS will continue to be used in the UK after VBP is
introduced and what their role is likely to be. METHODS: Stakeholders involved in
the current NICE health technology assessment process were interviewed to un-
derstand how PAS use may evolve following the introduction of VBP. Secondary
research was conducted of government proposals for VBP implementation, the
NICE response to VBP consultation and the current usage of PAS in the UK based on
NICE assessments and data from the IHS Global Insight Risk Sharing database.
RESULTS: With the advent of VBP, the price of a drug should in principle reflect its
value taking into account the level of uncertainty related to its efficacy. All drugs
that pass the VBP test should, in theory, be reimbursable, thus, eliminating the
need for a PAS that adjusts the cost of treatment allowing it to meet the UK’s ICER
per QALY threshold. Contrary to these expectations, primary research indicates
that PAS would continue to be used as payers attempt to secure a price lower than
the NICE-set VBP. CONCLUSIONS: PAS would remain a fact of life in the UK even
after VBP is implemented. This would apply not only for older drugs launched
before VBP, but also for new drugs and new indications marketed post-2013 be-
cause payers are expected to see the NICE-established VBP as a recommended
maximum price and attempt to negotiate that down through a PAS.
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OBJECTIVES: Defining and applying decision criteria are key to accountability and
reasonableness in decisionmaking and to ensure the most beneficial allocation of
health care resources. Objectives were to gather data on criteria considered by
policy and clinical decisionmakers in health care decisions globally.METHODS:An
online questionnaire was developed with 43 criteria organized into 10 clusters.
Using snowball sampling, decision makers were invited by an international task
force to report which criteria they consider and how these criteria weighed when
making decisions on health care interventions in their context. For each criterion,
respondents reported “currently considered”, “should be considered” and weight
assigned. Differences in proportions of participants reporting consideration of
each criterion were explored with inferential statistics across levels of decision
(micro, meso, macro), decision-maker perspective, and world region. RESULTS: A
total of 140 decision makers (1/3 clinical, 2/3 policy) from 23 countries in five con-
tinents completed the survey. Most relevant criteria (top ranked for “Currently
considered”, “Should be considered” and weights) were Clinical efficacy/effective-
ness, Safety, Quality of evidence, Disease severity and Impact on health care costs.
Organizational and skill requirements ranked high for consideration but low for
weights. For a majority of criteria, the number of decision makers reporting that
they ‘should be considered’ was higher than that reporting they are currently con-
sidered (P0.05). For more than 75% of criteria, there were no statistical differences
in proportions across levels of decision, perspective and world region. Differences
in proportions across several comparisons were statistically significant for criteria:
Population priorities, Stakeholder pressure/interests, Capacity to stimulate re-
search, Impact on partnership and collaboration, and Environmental impact
(P0.05). CONCLUSIONS: Results suggest a significant international agreement
among decision makers on the relevance of a core set of normative and feasibility
criteria and on the need to consider a wider range of criteria in decision-making
processes. Areas of divergence appear to be principally related to contextual as-
pects.
PHP140
CHALLENGES IN THE DATA COLLECTION REGARDING PATIENT POPULATION
AND TREATMENT COSTS FOR NON-DRUG INTERVENTIONS USING THE
EXAMPLE OF MORBUS DUPUYTREN
Kürschner N, Schiffner-Rohe J
Pfizer Deutschland GmbH, Berlin, Germany
OBJECTIVES: Since 2011, pharmaceutical companies have to submit a benefit as-
sessment dossier for new drugs in Germany. The dossier must contain information
about the additional benefit to an appropriate comparative therapy (ACT), costs
and the potentially targeted patient population. This work’s aim is to display the
challenges in collecting the information for Xiapex®, approved for treatment of
Dupuytren’s contracture in patients with a palpable cord, which was compared to
limited fasciectomy.METHODS:A systematic literature review, national and inter-
national, was used to determine epidemiological figures and cost data. Where no
information was available, necessary data was assessed from claim data. To deter-
mine the percentage of patients with palpable cord a Delphi study was conducted
with office based hand surgeons and orthopaedists. RESULTS: No valid data basis
was found for national epidemiological figures. Estimations based on European
prevalence data (1,7%-2,4%) lead to 1,34-1,9 Mio. Germans affected by Mb. Du-
puytren. Thereof, approx. 35.800 surgeries are conducted in Germany per year. The
Delphi-study revealed an estimation of 53,5% patients with palpable cord, resulting
in 19.153 patients eligible to Xiapex® treatment. No literature was found for treat-
ment costs of Mb. Dupuytren. Actual costs (inpatient and outpatient care plus
additional costs) were therefore selected from available claim data resulting in a
weighted average of 2087,58€ per patient and year. CONCLUSIONS: With a surgical
procedure as ACT, dossier developers have to face challenges due to the lack of
transparent, publically available data. Best available sources were used to gather
the information needed. The fact that the German IQWiG challenged our data
within the benefit assessment process without being able to provide better sources
of information underlines the necessity of an improvement regarding the availabil-
ity and open access to suitable data. This will increase validity of data in the
required dossier for an informed consequent decision making.
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EFFECTS OF CHANGING HEALTH POLICY ON PHARMACOECONOMICS AND
HEALTH OUTCOME STUDIES IN TURKEY
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